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The prognostic relevance of minimal residual disease (MRD) in patients with multiple myeloma is still an
open question. In bone marrow, the level of residual myeloma cells is associated with treatment outcome, but
the role of clonotypic cells in the peripheral blood (PB) for the prognosis of patients is not identiﬁed yet. In
this study, we retrospectively analyzed MRD by quantitative real-time IgH-PCR (IgH-qPCR) in the PB of 42
patients undergoing high-dose therapy followed by autologous PB stem cell transplantation as ﬁrst-line
therapy for multiple myeloma. The MRD level of PB samples was in median 40-fold lower than in bone
marrow samples, collected on the same day, with a wide intra- and interindividual variation (range, .4- to
4628-fold). The presence or absence of detectable MRD levels in PB did not correlate with the serological
remission status. Still, patients with negative PCR results in PB 3 months after high-dose therapy and PB stem
cell transplantation had lower International Staging System stage (P ¼ .01), lower levels of b2-microglobulin
(P ¼ .02), higher hemoglobin levels (P ¼ .01), and a prolonged event-free (median, 15 versus 4 months; P ¼
.004) and overall (median, 52 versus 17 months; P ¼ .03) survival. Importantly, by sequential monitoring of
clonotypic cells in PB, in 19 of 29 patients (66%) with progressive disease, an increase of the 2IgH/b-actin ratio
of at least 1 log step could be detected in median 4 months (range, .8 to 13 months) before the relapse was
diagnosed on the basis of the European Group for Blood and Marrow Transplantation criteria. These patients
with a molecular relapse in PB before a serological relapse had a signiﬁcantly shorter overall survival than
other patients (median, 17 months versus median not reached, P ¼ .02). In conclusion, IgH-qPCR is a sensitive
technique for the detection of clonotypic cells in PB, which precede clinical relapse. Future studies are needed
to evaluate whether these circulating tumor cells play a role in promoting disease recurrence.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Residual tumor cells in BM have a prognostic value in
Multiple myeloma (MM) is a B cell malignancy charac-
terized by a monoclonal expansion of plasma cells in bone
marrow (BM) and the secretion of paraprotein in the serum
and/or urine of patients. High-dose chemotherapy (HDT)
followed by autologous peripheral blood stem cell trans-
plantation (PBSCT) has improved the clinical outcome, but
eventually all patients relapse [1,2].
The quantitative measurement of minimal residual
disease (MRD) on a molecular level is a highly sensitive and
speciﬁc method to detect tumor cells of clonal origin [3,4]
that can help to estimate the risk of relapse. Evidence
shows that the achievement of a serological complete
remission (CR) is associated with a prolonged survival of
patients with MM [5]. Treatment protocols using chemo-
therapy in combination with novel agents such as bortezo-
mib [6] or lenalidomide [7,8] are continuously improving the
depth of response. Thus, the assessment of MRD becomes
more and more important, and the level of MRD may help to
guide therapeutic decisions in patients with MM in the
future [9], as it is already clinical practice in patients with
acute lymphoblastic leukemia or chronic myeloid leukemia
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lowed by autologous PBSCT, as has been shown by ﬂow
cytometry [12-14] and quantitative real-time IgH-PCR
(IgH-qPCR) [14-17]. In the same line are results from Corra-
dini et al. [18], who used qualitative IgH-PCR in BM samples
of 48 patients undergoing allogeneic PBSCT. In this setting,
negative MRD results were also associated with prolonged
overall survival (OS) and progression-free survival. Whereas
the prognostic impact of MRD in the BM is well documented,
experimental studies of MRD in PB of patients with MM are
rare, and patient numbers of reported results are very low
[19-23]. As with BM, ﬂuorescent activated cell sorter (FACS)
analysis or IgH-PCR are the methods of choice for the
detection of very low numbers of myeloma cells in the PB of
patients. To acquire more data on this topic, we used
IgH-qPCR [3,16] and sequentially measured the amount of
clone-speciﬁc cells in the PB of 42 patients with MM during
ﬁrst-line therapy with HDT and autologous PBSCT.METHODS
Patients and Samples
Patients were treated at our hospital between November 2000 and April
2008. All patients presented with symptomatic MM and received the same
ﬁrst-line therapy consisting of HDT followed by autologous PBSCT. The
induction treatment of all patients consisted of 2 to 4 cycles of idarubicine
(20 mg/m2 i.v., days 1 to 4) and dexamethasone (40 mg oral, days 1 to 4, 9 to
12, and 17 to 21) in monthly intervals. The patients then received pegﬁl-
grastim or granulocyte colony-stimulating factor in combination with
cyclophosphamide (2 g/m2, days 1 þ 2) for PB stem cell mobilization.
Thereafter, a single HDT was administered at a dose of 200 mg/m2
melphalan followed by autologous PBSCT.Transplantation.
Table 1
Patient Characteristics
MRD before Transplantation MRD after Transplantation
All Patients (n ¼ 42) Negative (n ¼ 12) Positive (n ¼ 9) P* Negative (n ¼ 24) Positive (n ¼ 8) P*
Age, median yrs (range) 54 (31-66) 54 (45-62) 55 (44-65) 1.0 54 (31-65) 55 (42-62) .8
Sex (male:female), % 67:33 75:25 67:33 1.0 67:33 63:38 1.0
Ig subtype (IgG:others), % 74:26 58:42 78:22 .6 67:33 75:25 1.0
Stage SþD (IþII:III), % 12:88 8:92 11:89 1.0 13:88 0:100 .6
Stage ISS (1:2:3), % 43:38:19 25:67:8 56:33:11 .3 58:33:8 0:63:38 .01
Cytogenetics (abnormal:normal), % 27:73 42:58 22:78 .6 22:78 25:75 1.0
CRP, median mg/dL (range) .5 (.3-9.8) .6 (.3-9.8) .7 (.3-1.8) .9 .6 (.3-9.8) .8 (.3-2.4) .8
LDH, median U/L (range) 160 (79-346) 149 (98-285) 171 (94-346) .5 149 (79-335) 227 (107-346) .08
Albumin, median g/dL (range) 3.9 (2.8-5.1) 3.6 (2.9-5.1) 4.2 (3.2-4.9) .08 4.0 (3.1-4.9) 3.7 (2.9-4.9) .3
b2-microglobulin, median mg/dL (range) 2.8 (1.2-15.3) 3.0 (1.5-8.5) 2.4 (1.6-8.0) .7 2.3 (1.2-8.5) 3.9 (2.1-10.2) .02
Hemoglobin, median g/dL (range) 11.1 (6.9-17.0) 11.0 (6.9-13.9) 11.4 (9.3-17.0) .1 11.7 (7.6-17) 9.2 (6.9-13.6) .01
Platelet count, median 103 (range) 261 (108-475) 239 (108-351) 320 (115-475) .3 259 (108-360) 245 (115-475) .8
Maintenance therapy (IFN:Thal:RIC), % 48:36:17 50:42:8 33:56:11 .7 42:46:13 63:25:13 .6
CRP indicates C-reactive protein; ISS, international staging system; LDH, lactate dehydrogenase; RIC, reduced-intensity conditioning allogeneic transplantation;
SþD, Salmon and Durie; Thal, thalidomide.
* Correlations were calculated by Fisher’s exact test for two categories, by chi-square test for three categories or the 2-tailed Mann-Whitney U test for
continuous variables.
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Figure 1. MRD in PB at a single time point. MRD levels in PB were analyzed in
samples obtained either at the time of ﬁrst diagnosis (n ¼ 12), approximately 1
week before (n ¼ 21) or 3 months after (n ¼ 32) HDT and PBSCT, or at the time
of relapse (n ¼ 22).
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with IFN-a (n ¼ 20) or thalidomide (n ¼ 15). IFN-a was given at a dose
between 1.0 and 4.5  106 U subcutaneously twice per week. The daily dose
of thalidomide varied between 100 and 400 mg. Maintenance therapy with
IFN-a or thalidomide was continued until disease progression or dis-
continued in case of toxicity. In case of an HLA-identical sibling donor, an
allogeneic transplantation was performed (n ¼ 7) after reduced-intensity
conditioning with ﬂudarabine 30 mg/m2 on days e3 to e1 and 2 Gy total
body irradiation on day 0. Remission status and disease progression were
deﬁned according to the European Group for Blood and Marrow Trans-
plantation (EBMT) criteria [24], with the only exception that a CR was not
conﬁrmed by a bone marrow biopsy.
All patients with a suitable MRD marker were included in the study
regardless of a negative or positive immunoﬁxation or the remission status
after HDT. We treated 121 patients with ﬁrst-line HDT and autologous
PBSCT. BM samples were obtained from 71 patients with MM of IgG/A
subtype at the time of diagnosis. For 57 of them (80%), we could establish
a patient-speciﬁc IgH-PCR. We included patients with the following criteria:
(1) at least 1 PB sample for MRD detection obtained after HDTand (2) in case
of clinical relapse, 1 sample at least 12 months before disease progression. A
total of 42 patients entered the analysis. Baseline characteristics of these
patients are listed in Table 1.
All patients gave written informed consent for treatment and molecular
analysis. The study was performed according to the guidelines of the ethical
committee of the University of Duesseldorf.
Sequencing of the Patient-Speciﬁc IgH Sequence and Real-Time
Quantitative IgH-PCR
IgH sequences were derived from total RNA preparations of BM samples
at the time of diagnosis, and a patient-speciﬁc IgH-qPCR was performed on
the LightCycler system (Roche, Mannheim, Germany) using Taqman tech-
nology as described [25]. The assays were performed as previously pub-
lished [16,25]. To achieve optimal speciﬁcity, an allelle-speciﬁc
oligonucleotide Taqman probe complementary to the complementarity
determining region 3 and an allelle-speciﬁc oligonucleotide sense primer
and an allelle-speciﬁc oligonucleotide antisense primer were designed.
IgH-PCR was performed according to previously published guidelines [26].
Instead of serial dilutions of DNA from the diagnostic samples with
known plasma cell inﬁltration, a serial 10-fold dilution of 103 to 105 plasmid
IgH copy numbers was used as an external, exogenous standard. As a refer-
ence for relative quantiﬁcation, a b-actin PCR was run on the same instru-
ment with the same DNA samples. Each patient-speciﬁc PCR reaction
required a minimal sensitivity of 104 (105 in 87% of cases) and a linear
ampliﬁcation within the quantitative range with r  .98. To conﬁrm
analytical speciﬁcity, no background ampliﬁcation of each IgH-PCR was
allowed using a pool of DNA fromhealthy donors. Negativity was ensured by
PCR without speciﬁc ampliﬁcation in 5 replicates, and the proportion of
clonotypic cells amongmononuclear cells was expressed as the 2IgH/b-actin
ratio in percent.
Statistical Analysis
OS and event-free survival(EFS) were measured from the time of ﬁrst
diagnosis and the time of HDT or from 3 months after HDT, respectively, to
the date of disease progression or death and analyzed by Kaplan-Meier plotsand the log rank test. Differences between nominal patient characteristics
were analyzed using Fisher’s exact test for 2 categories and the 2-tailed chi-
square test for 3 categories. Differences between continuous variables were
tested by two-tailed Mann-Whitney U test. Uni- and multivariate analyses
were performed using Cox regression analysis. For statistical analysis and
graphical representations, SPSS 15.0 (SPSS Inc., Chicago, IL), Microsoft Ofﬁce
Excel 2007 (Microsoft Corp., Redmond, WA) and Graphpad Prism (GraphPad
Software, San Diego, CA) were used.RESULTS
Samples and MRD Measurements
We measured the level of clonotypic cells by IgH-qPCR in
533 PB samples collected during the course of disease in 42
patients undergoing HDT and autologous PBSCT as ﬁrst-line
treatment for MM. Samples were available at the time of
diagnosis in 12 patients, approximately 1 week (median,
8 days; range, 3 to 30 days) before HDT in 21 patients and
approximately 3 months (median, 3.2 months; range, 2.0 to
4.4 months) after HDT in 32 patients (Figure 1). At time of
relapse, samples of 22 patients were available.
At time of diagnosis, clonotypic cells were detectable in
67% of PB samples (n ¼ 8) with a median MRD level of .001%
2IgH/b-actin ratio (median of positive samples, .02% 2IgH/b-
actin ratio; range, .001% to 2.5%). During the course ofﬁrst-line
Table 2
Correlation between the MRD Level and the Remission Status before or 3
Months after HDT and PBSCT
Remission Status before
Transplantation
nCR PR MRSD
MRD in PB before transplantation*
Negative 0 (0%) 9 (75%) 3 (25%)
Positive 2 (22%) 3 (33%) 4 (44%)
Remission Status 3 Mo after
Transplantation
nCR PR MRSD
MRD in PB after transplantationy
Negative 7 (29%) 16 (67%) 1 (4%)
Positive 2 (25%) 5 (63%) 1 (13%)
MRSD indicates minimal response/stable disease; nCR, near complete
remission; PR, partial remission.
* P ¼ .09.
y P ¼ .7. Signiﬁcance was calculated by chi-square test.
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Figure 2. Comparison of MRD levels of 67 paired samples from PB and BM of
36 patients. PB and BM samples were taken on the same day and represent
different time points during the course of disease. PCR results of paired
samples are indicated by lines.
Table 3
Correlation between the MRD Levels in BM and PB before or 3 Months after
HDT and PBSCT
MRD in PB before
Transplantation
Negative Positive
MRD in BM before transplantation*
Negative 3 (100%) 0 (0%)
Positive 9 (53%) 8 (47%)
MRD in PB after
Transplantation
Negative Positive
MRD in BM after transplantationy
Negative 3 (100%) 0 (0%)
Positive 14 (67%) 7 (33%)
* P ¼ .2.
y P ¼ .5. Signiﬁcance was calculated by Fisher’s exact test.
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stepwise reduced in comparison with the MRD levels at ﬁrst
diagnosis. This was shown by a lower detection rate of 43% in
samples obtained at the time before HDT (P ¼ .3, median of
positive samples, .02% 2IgH/b-actin ratio; range, .001% to .9%)
and only 25% in samples obtained 3months afterHDT (P¼ .03,
median MRD level in positive samples, .004% 2IgH/b-actin
ratio; range, .001% to .9%). At the timeof relapse, the numberof
tumor cells circulating in the PB was elevated and detectable
again in 73% of patients (P ¼ .002, median level in positive
samples, .04% 2IgH/b-actin ratio; range, .001% to 6.4%). In 6 of
22 patients the IgH-qPCR was negative at the time of relapse.
Surprisingly, we did not ﬁnd a signiﬁcant correlation
between remission rates, as deﬁned by the EBMTcriteria, and
MRD levels in PB, either before or 3 months after HDT and
PBSCT (Table 2). Interestingly, 4 patients with a CR had
positive PCR results in their PB samples, whereas 4 patients
who did not achieve a remission had negative PCR results at
the same time.
Comparison between MRD Level in BM and PB
At ﬁrst, we looked for the intraindividual varieties
between 67 paired samples from BM and PB that were taken
on the same day. These samples were obtained from 36
patients at different time points during the course of disease
(Figure 2). Overall, these PB samples had a medianMRD level
of 0% 2IgH/b-actin ratio (range, 0 to 6%) that was signiﬁcantly
lower than the median MRD level of .3% 2IgH/b-actin ratio in
the corresponding BM samples (range, 0 to 100%, P < .0001).
By direct comparison of paired positive PB and BM samples
(excluding pairs with negative PB samples), the MRD level in
BM was in median 40-fold higher than the MRD level in the
corresponding PB samplewith ratios ranging from .4 to 4628.
Paired PB and BM samples obtained before or 3 months
after HDT and PBSCT were available from 20 and 24 patients,
respectively. Although all PCR-negative BM samples were
also paired with PCR-negative PB samples, PCR-positive BM
samples (median, 2.3% 2IgH/b-actin ratio; range, .001% to
100%) were accompanied by PCR-positive results in 37% of
corresponding PB samples (median, .02% 2IgH/b-actin ratio;
range, .001% to 6%) (Table 3).
Prognostic Value of MRD in PB at a Single Time Point
We correlated MRD levels at 3 different time points,
namely at the time of ﬁrst diagnosis, 1 week before HDT andautologous PBSCT, and 3 months after transplantation, with
the clinical outcome of patients. Looking at MRD levels at the
time of ﬁrst diagnosis and treatment outcome, we found that
patients with negative PCR results (n ¼ 4) had a signiﬁcantly
prolonged EFS (P¼ .006) of median 66months in comparison
with patients with positive PCR results at this time point
(n¼ 8) and a median EFS of 26 months (Figure 3A). The OS of
these patients (median, 66 versus 53 months) was not
signiﬁcantly different (P ¼ .3), probably due to the low
number of cases (Figure 3B). On the other hand, the MRD
levels in PB samples obtained at the time before HDT had no
prognostic relevance in terms of EFS and OS (Figure 3C,D).
Interestingly, a negative PCR result in PB 3 months after HDT
was associated with a better treatment outcome.
Patients with a molecular remission in PB after HDT and
autologous PBSCT (n ¼ 24) had a signiﬁcantly prolonged EFS
of 15 months (P ¼ .004) in comparison with patients with
positive PCR results at this time point (n ¼ 8) and a median
EFS of 4 months (Figure 3E). Consistently, patients without
detectable MRD levels in PB after transplantation also had
a prolonged OS of 52 months (P ¼ .03) in comparison with
MRD-positive patients who had an OS of only 17 months
(Figure 3F). In line with this ﬁnding, MRD negativity in PB
after HDT was associated with other well-established prog-
nostic factors (Table 1), such as low International Staging
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Figure 3. Correlation of the MRD levels in PB at single time points with the clinical outcome of patients. The EFS of patients with negative or positive PCR results in PB
either at the time of ﬁrst diagnosis (A), 1 week before (C), or 3 months after (E) HDT and autologous PBSCT was analyzed by Kaplan-Meier plots and the log rank test.
Similarly, the OS of the patients with negative or positive PCR results at the time of ﬁrst diagnosis (B), before (D), or after (F) HDT and autologous PBSCT was analyzed.
FD indicates ﬁrst diagnosis; pre-MRD, MRD level before HDT and autologous PBSCT; post-MRD, MRD level after HDT and autologous PBSCT.
M. Korthals et al. / Biol Blood Marrow Transplant 19 (2013) 1109e11151112System stage (P ¼ .01), low b2-microglobulin (median,
2.3 mg/dL versus 3.9 mg/dL; P ¼ .02), and high levels of
hemoglobin (median, 11.7 g/dL versus 9.2 g/dL; P ¼ .01).
Prognostic Value of Sequential MRD Monitoring in PB
After a median follow-up of survivors of 45 months
(range, 13 to 80 months) after HDT, 29 of 42 patients (69%)
had suffered from relapse, whereas 13 patients (31%) were
still in ongoing remission. Sequential monitoring of clono-
typic cells in PB showed that in 19 of 29 patients (66%) with
progressive disease, a loss of molecular remission or an
increase of the 2IgH/b-actin ratio of more than 1 log step
could be observed (Figure 4). In these patients, the rise in
circulating clone-speciﬁc cells occurred in median 4 months
(range, .8 to 13 months) before the relapse was diagnosed byconventional diagnostic tests on the basis of the EBMT
criteria. In 10 patients negative results in PB could be docu-
mented until the time of relapse. Looking at the 13 patients
in ongoing remission, the duration of remission was in
median 45months (range,18 to 78months). TheMRD results
were continuously negative in 8 of these patients, whereas in
5 patients single positive results could not be conﬁrmed in
following samples.
Next, we investigated whether circulating tumor cells
detected before serological relapse were associated with
a poor prognosis. Therefore, we looked at all patients strat-
iﬁed according to whether or not they showed a molecular
relapse before serological relapse. The median OS from the
time of ﬁrst clinical relapse was 17 months and not reached,
respectively (P ¼ .02, Figure 5).
Figure 4. Sequential monitoring of MRD in PB. MRD levels in consecutive PB samples are shown for 29 patients with relapse after HDT and autologous PBSCT as
a function of time after HDT. One log steps of the 2IgH/b-actin ratio are depicted by circles with different color ﬁlls. In 19 patients (66%) an increase of the 2IgH/b-actin
ratio of more than 1 log step (arrows) could be detected in PB before clinical disease progression was observed.
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To date, monitoring of MRD by IgH-PCR or ﬂow cytometry
is not a standard diagnostic procedure in patients with MM
[9], but there is growing evidence that the measurement of
the level of residual tumor cells in the BM may help to
identify patients at different risk of relapse [12,16,18,25].
Although MRD assessment in BM is a valuable tool to eval-
uate treatment outcome, the role of MRD in the PB of
patients with MM is currently not clear.
In this study, we present data of 42 patients with MM
undergoing HDT and autologous PBSCT whowere monitored
for MRD in the PB by IgH-qPCR at different time points
during the course of disease. The absence of detectable MRD
levels in PB at the time of ﬁrst diagnosis as well as 3 months
after HDT was associated with a prolonged EFS and OS.
Moreover, by sequentially measuring residual clonotypic
cells in samples collected on a monthly basis, relapse could
be identiﬁed in median 4 months earlier than with conven-
tional diagnostic methods. Further, the appearance of clo-
notypic cells circulating in PB before the diagnosis of
a clinical relapse was also associated with a shorter OS.
When addressing the role of MRD in PB, the ﬁrst essential
question is whether there is a difference betweenMRD in BM
and PB. Our comparison of both compartments showed
a great difference in the level of clonotypic cells with a vari-
ation of the MRD ratio between BM and PB from less than 1
up to approximately 5000-fold without any patternaccording to sampling time point or remission status.
Therefore, the MRD level in PB is not only a mere reﬂection of
the MRD level in BM; as a result, in patients with MM it is
worth looking at MRD in both compartments.
The second question is whether MRD levels in PB at
a single time point are of prognostic relevance. Using ﬂow
cytometry, it has been shown that circulating myeloma cells
in the PB at a given time point are associated with a poor
outcome of patients undergoing HDT and autologous PBSCT.
This is true for the time of ﬁrst diagnosis [27], the time before
[28], and 3 months after [29] HDT and autologous trans-
plantation. Using IgH-PCR to detect MRD in PB, the published
patient numbers range from 6 to 20 [19-23]. In our study we
report results onmolecularMRD analysis in 42 patients using
IgH-qPCR. In line with the published data acquired by FACS
analysis [27-29], our data conﬁrm the poor prognosis of
circulating myeloma cells at the time of ﬁrst diagnosis and
also conﬁrm the prognostic beneﬁt of a response on a molec-
ular level in PB after HDT and autologous PBSCT in terms of
a prolonged EFS or OS. The absence or presence of detectable
myeloma cells in PB at this time point also correlated with
known prognostic factors such as International Staging
System stage and serum levels of lactate dehydrogenase and
b2-microglobulin, although there was no correlationwith the
remission status as deﬁned by the EBMT criteria.
Regarding the fact that the number of clonotypic cells in
PB do not correlate with the number in BM, it is tempting to
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Figure 5. Comparison of the survival of patients with a molecular relapse
before clinical relapse. The OS was calculated as time from clinical relapse and
analyzed by Kaplan-Meier plots and the log rank test.
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of MRD. Because of relatively low patient numbers with
paired PB and BM samples, we were not able to ﬁnally clarify
if MRD levels in PB and BM are of prognostic relevance in
a complementary manner.
The third question addresses the impact of MRD not only
at a single time point but as a sequential monitoring of
dynamic changes of the number of residual tumor cells
during times of clinical remission. In this ﬁeld, FACS data are
rare, whereas IgH-PCR studies [23,30,31] with small patient
numbers (n ¼ 1 to 6) showed that an increase in tumor load
could be detected in PB before disease progression was
proven by conventional means. We conﬁrm these data in our
group of 42 patients, where a molecular relapse could be
observed in 66% of 29 patients with progressive disease in
median 4 months before the clinical relapse was diagnosed.
Moreover, we show that patients with a molecular relapse
preceding clinical relapse have a very short survival after
disease progression. This interesting ﬁnding hints at a role of
these clonotypic cells in spreading the disease, which should
be further investigated. It will also be of interest to see
whether new agents may be effective in overcoming the bad
prognosis associated with these circulating tumor cells.
On the other hand, the clinical relevance of this ﬁnding is
relatively small, because most physicians will not treat
patients with MM due to a molecular relapse, in the same
way they do not treat patients with relapse from CR unless
the clinical relapse is associated with increasing disease
activity or end-organ damage [32]. In combination with the
fact that IgH-PCR can only be applied to about 75% of patients
due to technical reasons [14,16,25], we do not see a great
potential in the future of MRD detection in the PB as a routine
diagnostic tool for all patients with MM. However, IgH-qPCR
may be a very suitable tool to evaluate therapy response to
investigational drugs, whose mechanism of action often are
not completely understood, and to deﬁne the origin of drug-
resistant tumor cells.
In conclusion, molecular remission in PB is a prognostic
parameter for a prolonged EFS and OS, and monthlymonitoring of MRD can help to detect disease progression
earlier than conventional diagnostic methods. Even though
the clinical utility is limited, evaluation of MRD in PB by IgH-
qPCR may help us to better understand the pathophysiology
of disease recurrence during therapy with investigational
agents in the future.ACKNOWLEDGMENTS
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